Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
29.10
+0.10 (0.34%)
At close: Jun 12, 2026, 4:00 PM EDT
29.68
+0.58 (1.99%)
After-hours: Jun 12, 2026, 5:09 PM EDT
Neurogene Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
131
Market Cap
459.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 925.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 180.25M |
| Sutro Biopharma | 99.61M |
| Arvinas | 89.40M |
| 4D Molecular Therapeutics | 88.24M |
| Assembly Biosciences | 71.10M |
| Prothena Corporation | 57.94M |
| C4 Therapeutics | 34.86M |
NGNE News
- 4 days ago - Neurogene completes dosing in Embolden trial of NGN-401 - TheFly
- 4 days ago - Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome - Business Wire
- 9 days ago - Neurogene Transcript: AGM 2026 - Transcripts
- 9 days ago - Neurogene initiated with a Buy at Rodman & Renshaw - TheFly
- 10 days ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Neurogene reports Q1 EPS ($1.39), consensus ($1.27) - TheFly
- 4 weeks ago - Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates - Business Wire
- 4 weeks ago - Neurogene Quarterly report: Q1 2026 - Filings